BCPC earnings analysis
What we found in BCPC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Balchem Corporation reported impressive Q1 2026 results with revenues of $270.7 million and EPS of $1.33, both surpassing analyst expectations. Revenue increased by 8.1% compared to Q1 2025, reflecting strong performance across all segments, particularly Human Nutrition & Health, which grew by 8.3%. The company also showed effective management of operating expenses, although they experienced a notable increase due to higher compensation costs.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth
- Q1 2026 revenue reached $270.7 million, up 8.1% from $250.5 million in Q1 2025.
- Strong EPS
- Diluted EPS for Q1 2026 was $1.33, matching consensus estimates.
- Segment Growth
- Human Nutrition & Health segment rose by 8.3% to $171.6 million, driven by increased volumes.
- Improved Gross Margin
- Gross margin increased to 37.3% in Q1 2026 from 35.2% in Q1 2025.
- Operating Cash Flow Up
- Operating cash flow for Q1 2026 increased to $40.1 million, up 9.9% from $36.5 million last year.
- Significant Share Repurchases
- Share repurchases in Q1 2026 totaled $15.7 million, up from $5.3 million in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increased Operating Expenses
- Operating expenses grew 22.4% to $45.5 million from $37.2 million in Q1 2025, mainly due to higher compensation.
- Geopolitical Tensions
- Heightened geopolitical tensions may lead to increased energy prices and raw material costs, impacting operations.
- Raw Material Inflation
- Continued inflation in raw materials may pressure margins despite improved sales.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $1.33
- Gross margin
- 37.3%
- Operating margin
- 20.5%
- Segment
- Human Nutrition & Health $171.6M
- Segment
- Animal Nutrition & Health $62.2M
- Segment
- Specialty Products $34.7M
What they said about what is next.
No specific quantitative guidance provided, forward-looking statements indicate monitoring of costs and economic conditions.
The filing reads better than the one before it.
What came before.
- 10-K · February 20, 2026
- Balchem describes a product-led growth strategy focused on differentiated human and animal nutrition ingredients, microencapsulation and specialty gases, investing in R&D and manufacturing capacity. 2025 showed…
- 10-Q · October 21, 2025
- Balchem reported Q3 net sales of $267.6M and diluted EPS of $1.24, both ahead of year‑ago levels. Gross margin and operating margin improved modestly to 35.7% and 20.4%, respectively, while operating cash flow for the…
- 10-Q · July 31, 2025
- Balchem reported Q2 net sales of $255,467,000 (up $21,386,000 vs. Q2 2024) and diluted EPS of $1.17, both modestly ahead of consensus. Gross margin improved to 36.5% (93,113/255,467) and operating income rose to…
- 10-K · February 21, 2025
- Balchem emphasizes premium, science-backed growth in Human Nutrition & Health (HNH) and Animal Nutrition & Health (ANH) while maintaining a Specialty Products business that includes performance gases. Management…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BCPC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever